Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemia-reperfusion injury

Physiological Reports

Volumn 3, Issue 1, 2015, Pages

  House, Stacey L ^a   Wang, Joy ^a   Castro, Angela M ^a   Weinheimer, Carla ^a   Kovacs, Attila ^a   Ornitz, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac repair; Cardioprotection; FGF2; Fibroblast growth factor; Ischemia reperfusion injury; Myocardial infarction

Indexed keywords

FIBROBLAST GROWTH FACTOR 2;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FGF2 GENE; GENE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOLOGY; MALE; MOUSE; NONHUMAN; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ST SEGMENT ELEVATION; TRACHEOSTOMY; TUNEL ASSAY;

EID: 85006778840     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.14814/phy2.12278     Document Type: Article

References (38)

1. American Heart Association. 2010. Heart disease and stroke statistics-2010 update. American Heart Association, Dallas, TX.
2. Bauer, M., S. Cheng, M. Jain, S. Ngoy, C. Thodoropoulos, A. Trujillo, et al. 2011. Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice. Circ. Res. 108:908-916.
3. Detillieux, K. A., P. A. Cattini, and E. Kardami. 2004. Beyond angiogenesis: the cardioprotective potential of fibroblast growth factor-2. Can. J. Physiol. Pharmacol. 82:1044-1052.
4. Eguchi, M., G. Xu, R. K. Li, and G. Sweeney. 2012. Diabetes influences cardiac extracellular matrix remodelling after myocardial infarction and subsequent development of cardiac dysfunction. J. Cell Mol. Med. 16:2925-2934.
5. Goncalves, L. M. 1998. Fibroblast growth factor-mediated angiogenesis for the treatment of ischemia. Lessons learned from experimental models and early human experience. Rev. Port. Cardiol. 17 (Suppl. 2):II11-II20.
6. Hall, J. L., S. Grindle, X. Han, D. Fermin, S. Park, Y. Chen, et al. 2004. Genomic profiling of the human heart before and after mechanical support with a ventricular assist device reveals alterations in vascular signaling networks. Physiol. Genomics 17:283-291.
7. House, S. L., C. Bolte, M. Zhou, T. Doetschman, R. Klevitsky, G. Newman, et al. 2003. Cardiac-specific overexpression of fibroblast growth factor-2 protects against myocardial dysfunction and infarction in a murine model of low-flow ischemia. Circulation 108:3140-3148.
8. House, S. L., K. Branch, G. Newman, T. Doetschman, and J. Schultz. 2005. Cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 is mediated by the MAPK cascade. Am. J. Physiol. Heart Circ. Physiol. 289: H2167-H2175.
9. House, S. L., S. J. Melhorn, G. Newman, T. Doetschman, and J. Schultz. 2007. The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2. Am. J. Physiol. Heart Circ. Physiol. 293:H354-H365.
10. House, S. L., G. Newman, and J. E. Schultz. 2010a. Human recombinant low molecular weight fibroblast growth factor 2 (FGF2) protects the heart from reperfusion injury through activation of FGF receptors and nitric oxide signaling. Ann. Emerg. Med. 56:S5.
11. House, S. L., B. E. House, B. Glascock, T. Kimball, E. Nusayr, J. E. Schultz, et al. 2010b. Fibroblast growth factor 2 mediates isoproterenol-induced cardiac hypertrophy through activation of the extracellular regulated kinase. Mol. Cell Pharmacol. 2:143-154.
12. Jiang, Z. S., G. B. Wen, Z. H. Tang, W. Srisakuldee, R. R. Fandrich, and E. Kardami. 2009. High molecular weight FGF-2 promotes postconditioning-like cardioprotection linked to activation of protein kinase C isoforms, as well as Akt and p70 S6 kinases. [corrected]. Can. J. Physiol. Pharmacol. 87:798-804.
13. Kanno, S., D. L. Lerner, R. B. Schuessler, T. Betsuyaku, K. A. Yamada, J. E. Saffitz, et al. 2002. Echocardiographic evaluation of ventricular remodeling in a mouse model of myocardial infarction. J. Am. Soc. Echocardiogr. 15:601-609.
14. Kardami, E., K. Detillieux, X. Ma, Z. Jiang, J. J. Santiago, S. K. Jimenez, et al. 2007. Fibroblast growth factor-2 and cardioprotection. Heart Fail. Rev. 12:267-277.
15. Lavine, K. J., A. Kovacs, C. Weinheimer, and D. L. Mann. 2013. Repetitive myocardial ischemia promotes coronary growth in the adult mammalian heart. J. Am. Heart Assoc. 2:e000343.
16. Lavine, K. J., and D. M. Ornitz. 2010. The epicardial signaling center in development and disease. Pp. 345-359 in N. Rosenthal and R. Harvey, eds. Heart development and regeneration. Elsevier Inc., London.
17. Liao, S., J. R. Bodmer, M. Azhar, G. Newman, J. D. Coffin, T. Doetschman, et al. 2010. The influence of FGF2 high molecular weight (HMW) isoforms in the development of cardiac ischemia-reperfusion injury. J. Mol. Cell. Cardiol. 48:1245-1254.
18. Lu, S. Y., D. P. Sontag, K. A. Detillieux, and P. A. Cattini. 2008. FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development. Am. J. Physiol. Cell Physiol. 294: C1242-C1249.
19. Manning, J. R., G. Carpenter, D. R. Porter, S. L. House, D. A. Pietras, T. Doetschman, et al. 2012. Fibroblast growth factor-2-induced cardioprotection against myocardial infarction occurs via the interplay between nitric oxide, protein kinase signaling, and ATP-sensitive potassium channels. Growth Factors 30:124-139.
20. Miyake, A., M. Konishi, F. H. Martin, N. A. Hernday, K. Ozaki, S. Yamamoto, et al. 1998. Structure and expression of a novel member, FGF-16, on the fibroblast growth factor family. Biochem. Biophys. Res. Commun. 243:148-152.
21. Murphy, E., and C. Steenbergen. 2008. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88:581-609.
22. Murry, C. E., R. B. Jennings, and K. A. Reimer. 1986. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 74:1124-1136.
23. Nossuli, T. O., V. Lakshminarayanan, G. Baumgarten, G. E. Taffet, C. M. Ballantyne, L. H. Michael, et al. 2000. A chronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies. Am. J. Physiol. Heart Circ. Physiol. 278:H1049-H1055.
24. Oladipupo, S. S., C. Smith, A. Santeford, C. Park, A. Sene, L. A. Wiley, et al. 2014. Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis. Proc. Natl Acad. Sci. USA 111:13379-13384.
25. Ornitz, D. M., and N. Itoh. 2001. Fibroblast growth factors. Genome Biol. 2:REVIEWS3005.
26. Ornitz, D. M., and N. Itoh. 2015. The fibroblast growth factor signaling pathway. Wiley Interdiscip. Rev. Dev. Biol. in press.
27. Pellieux, C., A. Foletti, G. Peduto, J. F. Aubert, J. Nussberger, F. Beermann, et al. 2001. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J. Clin. Invest. 108:1843-1851.
28. Schultz, J. E. 2002. FGF and the cardiovascular system. Pp. 45-66 in P Cuevas, ed. Fibroblast growth factors in the cardiovascular system. I. Holzapfel Publishers, Munich.
29. Schultz, J. E., S. A. Witt, M. L. Nieman, P. J. Reiser, S. J. Engle, M. Zhou, et al. 1999. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J. Clin. Invest. 104:709-719.
30. Srisakuldee, W., Z. Makazan, B. E. Nickel, F. Zhang, J. A. Thliveris, K. B. Pasumarthi, et al. 2014. The FGF-2-triggered protection of cardiac subsarcolemmal mitochondria from calcium overload is mitochondrial connexin 43-dependent. Cardiovasc. Res. 103:72-80.
31. Tyagi, S. C. 1997. Vasculogenesis and angiogenesis: extracellular matrix remodeling in coronary collateral arteries and the ischemic heart. J. Cell. Biochem. 65:388-394.
32. Virag, J. A., M. L. Rolle, J. Reece, S. Hardouin, E. O. Feigl, and C. E. Murry. 2007. Fibroblast growth factor-2 regulates myocardial infarct repair: effects on cell proliferation, scar contraction, and ventricular function. Am. J. Pathol. 171:1431-1440.
33. Vyas, A. K., L. B. Aerni-Flessner, M. A. Payne, A. Kovacs, P. Y. Jay, and P. W. Hruz. 2012. Saxagliptin improves glucose tolerance but not survival in a Murine model of dilated cardiomyopathy. Cardiovasc. Endocrinol. 1:74-82.
34. Wang, J., D. Sontag, and P. A. Cattini. 2014. Heart-specific expression of FGF-16 and a potential role in postnatal cardioprotection. Cytokine Growth Factor Rev. in press.
35. World Health Organization. 2014. The top ten causes of death. p. 1-5. World Health Organization, Geneva, Switzerland.
36. Zhao, T., W. Zhao, Y. Chen, R. A. Ahokas, and Y. Sun. 2011. Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction. Int. J. Cardiol. 152:307-313.
37. Zhou, M., R. L. Sutliff, R. J. Paul, J. N. Lorenz, J. B. Hoying, C. C. Haudenschild, et al. 1998. Fibroblast growth factor 2 control of vascular tone. Nat. Med. 4:201-207.
38. Zhou, W., X. Feng, Y. Wu, J. Benge, Z. Zhang, and Z. Chen. 2009. FGF-receptor substrate 2 functions as a molecular sensor integrating external regulatory signals into the FGF pathway. Cell Res. 19:1165-1177.